Disclosure of Conflicts of Interest
The authors declare no competing financial interests.
Reference
[1] Young NS. Aplastic anemia. N Engl J Med. 2018;379(17):1643–1656.
[2] Montane E, Ibanez L, Vidal X, et al. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica. 2008;93(4):518–523.
[3] Helge D Hartung, Timothy S Olson, Monica Bessler. Acquired aplastic anemia in children. Pediatric clinics of North America 2013 Dec;60(6):1311-36.
[4] Scott A Peslak, Timothy Olson, Daria V Babushok. Diagnosis and Treatment of Aplastic Anemia[J]. Current Treatment Options in Oncology, 2017, 18(12):70.
[5] Scheinberg P, Wu C O, Nunez O, et al. Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine. [J]. Journal of Pediatrics, 2008, 153(6):814-819.e1.
[6] Rogers Z R, Nakano T A, Olson T S, et al. Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study[J]. Haematologica, 2019.
[7] Yoshida N, Kobayashi R, Yabe H, et al. First-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapy. [J]. Haematologica, 2014, 99(12):1784-91.
[8] Carlo, Dufour, Marta, et al. Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. [J]. Haematologica, 2014, 99(10):1574-81.
[9] Garanito M P, Carneiro J D A, Filho V O, et al. Outcome of children with severe acquired aplastic anemia treated with rabbit antithymocyte globulin and cyclosporine A, [J]. Jornal de Pediatria, 2014.
[10] Dufour C, Pillon M, G Sociè, et al. Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant. [J]. British Journal of Haematology, 2015, 169.
[11] Townsley D M, Scheinberg P, Winkler T, et al. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia[J]. New England Journal of Medicine, 2017, 376(16):1540-1550.
[12] Matthew J Olnes, Phillip Scheinberg, Katherine R Calvo, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. The New England journal of medicine 2012 Jul 05;367(1):11-9.
[13] Régis Peffault de Latour, Austin Kulasekararaj, Simona Iacobelli, et al. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia. The New England journal of medicine 2022 01 06;386(1):11-23
[14] Emma M. Groarke, Bhavisha A. Patel, Fernanda Gutierrez-Rodrigues, et al. Eltrombopag added to immunosuppression for children with treatment naive severe aplastic anaemia[J]. British Journal of Haematology, 2021, 192, 605–614.
[15] Harry Lesmana, Timothy Jacobs, Michelle Boals, et al. Eltrombopag in children with severe aplastic anemia. Pediatric blood & cancer 2021 08;68(8): e29066.
[16] Olga Goronkova, Galina Novichkova, Tatiana Salimova, et al. Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemia. Blood advances 2022 Apr 21.
[17] Subspecialty Group of Hematology, Society of Pediatrics, Chinese Medical Association The
Editorial Board, Chinese Journal of Pediatrics. Recommendations for diagnosis and treatment of acquired aplastic anemia in children. Zhonghua Er Ke Za Zhi. 2014;52(2):103–106.
[18] Erickson-Miller C. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist[J]. Stem Cells, 2009, 27.
[19] Filippidou M, Avgerinou G, Tsipou H, et al. Longitudinal evaluation of eltrombopag in paediatric acquired severe aplastic anaemia. Br J Haematol. 2020;190(3): e157–e173. doi:10.
1111/bjh.16766.
[20] Kim TO, Despotovic J, Lambert MP. Eltrombopag for use in children with immunethrombocytopenia. Blood Adv. 2018;2(4):454–461. doi:10.1182/bloodadvances.2017010660.
Table 1: Characteristics of the patients at baseline